Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2001
Event: Acquisition of Union Biometrica, Inc. via merger into a wholly-owned subsidiary.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial results. The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels for the reporting period.
| Transaction Component | Value |
|---|---|
| Common Stock Issued | Approximately 659,282 shares |
| Cash Consideration | Approximately $7.5 million |
| Stock Options Granted | Options to purchase approximately 263,202 shares |
| Escrow Shares | 484,312 shares (held to secure indemnification) |
Material Changes
- Acquisition: Harvard Bioscience acquired Union Biometrica, a developer of instruments and assays for automated handling of model organisms.
- Accounting Treatment: The merger is accounted for as a purchase transaction.
- Capital Structure: The company issued new equity and options and utilized cash reserves to fund the deal.
Guidance, Outlook, and Risks
Management Commentary: The company intends to continue using the acquired assets for the development and commercialization of Union Biometrica's technology. The purchase price was negotiated at arm's length with no material relationships between the parties.
Risks and Uncertainties: The filing highlights several forward-looking risks, including:
- Uncertainty regarding the financial impact of the acquisition on future results and whether it will be accretive to earnings.
- Risks related to the technology, applications, and customer acceptance of Union Biometrica products.
- Potential impact on the company's stock price and operations.
- Risk of inability to develop or acquire additional products to expand offerings.
Pro Forma Information: Required pro forma financial information and financial statements of the acquired business are not included in this filing but will be filed by amendment no later than August 14, 2001.
Investor Verification Checklist
- Verify the pro forma financial impact of the acquisition once filed by August 14, 2001.
- Confirm the release schedule of the 484,312 escrowed shares (two-thirds after 12 months, one-third after 24 months).
- Assess the integration progress of Union Biometrica's automated handling systems into Harvard Bioscience's product line.
- Monitor cash flow implications given the $7.5 million cash outlay funded by working capital and IPO proceeds.